dolasetron (Anzemet)

Also Known As:

Anzemet; 1H-indole-3-carboxylic acid, (6R,9AS)-octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl ester, rel-, methanesulfonate, hydrate (1:1:1); 1H-indole-3-carboxylic acid, octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl ester, (2-alpha,6-alpha,8-alpha,9a-beta)-; 1H-indole-3-carboxylic acid-trans-octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl ester methanesulfonate; MDL 73,147EF; MDL 73147EF; MDL-73147EF; dolasetron mesilate monohydrate; dolasetron mesylate; dolasetron mesylate monohydrate; indole-3-carboxylic acid, ester with (8R)-hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-one; octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl 1H-indole-3-carboxylate

Networked: 148 relevant articles (53 outcomes, 57 trials/studies)

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - dolasetron: 148
    - Quinolizines: 1
      - dolasetron: 148

Experts

1.	Fujii, Yoshitaka: 4 articles (12/2011 - 01/2005)
2.	Boldt, J: 4 articles (11/2006 - 04/2001)
3.	Maleck, W H: 4 articles (11/2006 - 04/2001)
4.	Piper, S N: 4 articles (11/2006 - 04/2001)
5.	Kranke, P: 3 articles (08/2007 - 02/2003)
6.	Röhm, K D: 3 articles (11/2006 - 09/2002)
7.	Kovac, A L: 3 articles (02/2000 - 01/2000)
8.	Faria, Claudio: 2 articles (05/2014 - 01/2014)
9.	Janicki, Piotr K: 2 articles (01/2012 - 04/2006)
10.	Boldt, Joachim: 2 articles (04/2008 - 12/2002)

Related Diseases

1.	Postoperative Nausea and Vomiting (PONV) 08/01/1997 - "Single intravenous or oral dolasetron doses ranging from 12.5 to 100 mg and 25 to 200 mg, respectively, were significantly more effective than placebo in preventing postoperative nausea and vomiting (PONV) in female surgical patients. " 02/01/2000 - "To identify the maximally effective dolasetron dose (i.e., maximum efficacy with minimum adverse events) for prevention of postoperative nausea and vomiting (PONV) using the statistical power generated in a pooled patient sample from three large, nearly identical clinical trials. " 09/01/1997 - "Dolasetron is effective for treating PONV and has an adverse event profile similar to that of placebo. " 02/01/2003 - "This prospective, randomized, double-blind study was performed to evaluate the efficacy of prophylaxis with dolasetron in reducing the frequency of postoperative nausea and duration of discharge time. " 12/01/2002 - "The results of our study suggest that dolasetron was more effective than MCP and placebo in preventing PONV. "
2.	Vomiting 07/01/2003 - "The purpose of this study was to assess the efficacy and safety of dolasetron for the prevention of emesis comparing a single 0.35 mg.kg-1 or 12.5 mg dose with placebo. " 04/01/2008 - "Dolasetron (11%) significantly reduced vomiting in comparison with the DHB (52%) and placebo group (52%). " 12/01/2004 - "To prevent delayed emesis, dolasetron 200 mg p.o. " 09/15/2000 - "Oral dolasetron 100 or 200 mg once daily also prevented emesis. " 03/15/1997 - "Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. "
3.	Nausea 02/01/2003 - "The frequency (Group 1/Group 2; 20/55%; P<0.05) and mean (SD) maximal intensity [15 (9)/45 (14) mm; P<0.05] of nausea during 24 h was significantly reduced after dolasetron and discharge times in Group 1 were less than Group 2 [22 (14)/45 (28) min; P<0.05]." 03/01/2001 - "Dolasetron for chemo nausea." 02/01/2000 - "All four dolasetron doses produced significant increases in complete response and decreases in maximum VAS nausea compared with placebo (p < 0.01). " 01/01/2000 - "In females, dolasetron, 12.5-mg, dolasetron provided maximum clinical benefit (effectiveness compared with adverse events), with no additional benefit in complete response rates or nausea visual analogue scale scores at higher doses. " 03/01/1998 - "Percentage of patients with no nausea and patient satisfaction scores were significantly higher for each dolasetron dose group than placebo (p < or = 0.047 and p < or = 0.004, respectively). "
4.	Neoplasms (Cancer) 07/01/1999 - "These results support further evaluation of oral dolasetron in larger randomized clinical trials in the pediatric cancer population." 03/15/1997 - "Single oral doses of dolasetron mesylate were found to be effective in preventing acute emesis in cancer patients receiving moderately emetogenic chemotherapy." 08/01/1999 - "Open-label comparison of the antiemetic efficacy of single intravenous doses of dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy." 07/01/1999 - "Safety, tolerability, antiemetic efficacy, and pharmacokinetics of oral dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy." 05/01/1999 - "Pharmacokinetics of intravenous dolasetron in cancer patients receiving high-dose cisplatin-containing chemotherapy."
5.	Pain (Aches) 05/01/2011 - "Reduction in pain intensity at M3 was significantly greater in dolasetron-treated patients (p = 0.04, -21.3 on a 0-100 scale) compared with placebo controls (-5.9). " 05/01/2011 - "More patients in the dolasetron group had ≥ 30% and ≥ 50% improvement in pain (42.5% and 28% respectively in the dolasetron group versus 25% and 16% in the placebo group). " 05/01/2011 - "Intermittent IV dolasetron was safe and efficacious for the reduction of pain intensity associated with FM at 3 months." 09/01/2002 - "Severity, but not incidence of pain on injection was significantly reduced by dolasetron (50 %) compared with placebo. " 05/01/2011 - "The purpose of the study was to evaluate the efficacy and safety of dolasetron for symptomatic relief of pain associated with fibromyalgia (FM). "

Related Drugs and Biologics

1.	Ondansetron (Zofran)
2.	Antiemetics
3.	Granisetron (Kytril)
4.	Dexamethasone (Maxidex)
5.	Droperidol
6.	Metoclopramide (Reglan)
7.	Mesylates (Mesylate)
8.	Cisplatin (Platino)
9.	Tropisetron (Navoban)
10.	Palonosetron (Aloxi)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Ambulatory Surgical Procedures (Outpatient Surgery)
3.	Therapeutics
4.	Hysterectomy
5.	Anesthesia